Free Trial!
Today’s Best Stocks To Trade! Click Here
The International Diabetes Federation (IDF) BRIDGES translational research grant program will fund a pilot study in the Philippines that will offer culturally appropriate and improved diabetes care in rural communities using local health workers.
The community-based study, Diabetes Self-Management Program (DSME), will help Filipinos with diabetes to acquire the knowledge, self-care practices, and attitudes required for the effective management of their diabetes. The Section of Endocrinology, Diabetes, and Metabolism of the University of the Philippines -- the Philippine General Hospital will launch the pilot study in San Juan, Batangas, Philippines.
"The IDF BRIDGES Research Grant will be instrumental in making this ambitious community-based diabetes program a reality. This pilot study is part of a long-term, self-sustaining, comprehensive diabetes program which aims at reducing the burden of diabetes and aspires to be a 'model of community diabetes care' throughout the country, ultimately attenuating disparities in health outcomes for underserved Filipinos in the rural community," said Dr. Gregory A. Ardena, study co-investigator.
The Federation, through BRIDGES, is committed to converting research findings into useful practices for the provision of quality care and services delivered by healthcare providers. The diabetes education program in the Philippines, along with the 10 other selected translational research projects, was chosen because of its innovative idea, demonstration of the potential for health care cost savings, sustainability plans and the opportunity for its results to be widely replicated in other settings.
The education program will offer culturally-appropriate, comprehensive diabetes education by using locally adapted educational materials, with the support of Barangay Health Workers (BHW) as health educators. The pilot study is part of a long-term, self-sustaining diabetes program which aims at reducing the burden of diabetes by improving self-care and behaviour.
"The Filipino Diabetes Self-Management Program goes to the heart of what the International Diabetes Federation BRIDGES program aims to achieve," said Linda Siminerio, Chair of the IDF BRIDGES Review Committee. "This program has the potential to improve the lives of people living with diabetes and increase diabetes knowledge among the Barangay Health Workers who will now have the capacity to support quality care."
The International Diabetes Federation independently manages the BRIDGES program with an educational grant from Eli Lilly and Company and is committed to promoting diabetes care, prevention and a cure worldwide.
The International Diabetes Federation (IDF) is the global advocate for the over 250 million people with diabetes worldwide. It represents over 200 diabetes associations in more than 160 countries. Its mission is to promote diabetes care, prevention and a cure worldwide. The International Diabetes Federation is an NGO in official relations with the World Health Organization and an associated NGO with the United Nations Department of Public Information. The International Diabetes Federation leads the World Diabetes Day and Unite for Diabetes campaign. Additional information is available at www.idf.org.
BRIDGES is the global translational grant programme of the International Diabetes Federation. It solicits proposals that support cost effective and sustainable interventions that can be adopted in real world settings, for the prevention and control of diabetes. Projects should be based on interventions already proven to be effective in trials to prevent and treat diabetes, to improve care of type 1 and type 2 diabetes and delay its complications. The interventions proposed should have the potential to be widely disseminated to clinical practice, individuals and communities. For more information, visit http://www.idfbridges.org.
The Section of Endocrinology, Diabetes, and Metabolism of the University of the Philippines -- Philippine General Hospital provides opportunities for the independent and funded research activities involving section consultants and fellows-in-training. These efforts have gained recognition locally, nationally and internationally.
CONTACT: Kerrita McClaughlyn,
Media Relations Manager of International Diabetes Federation,
Tel +32-2-5431639,
Mobile +32 487 530 625,
media@idf.org,
or Dr. Michael Tee,
Spokesperson for Philippine General Hospital,
Tel +63-2-5218450,
Mobile +63 917 833 6398,
michaeltee@yahoo.com
Web site: http://www.idf.org
http://www.idfbridges.org
SOURCE: International Diabetes Federation
Press Release
Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development
CORAL GABLES, Fla., May 7 / PPI Press Release/ --
Acquisition of dermal filler product enhances company's aesthetic portfolio
Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, announced today that it has acquired ABR Invent and ABR Development, developers of the dermal filler Atlean(R). Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both ABR Invent and ABR Development are legal entities based in France.
"Stiefel Laboratories has been looking for the right dermal filler to add to our aesthetic portfolio for quite some time," said Charles W. Stiefel, chairman and CEO, Stiefel Laboratories. "After conducting due diligence and extensive research, our team made an offer to ABR Development, a company whose innovation, expertise and product portfolio will significantly strengthen our position in the global aesthetics market. We are delighted that our proposal was accepted."
Atlean(R) dermal filler is currently commercialized in France and Italy and distribution and manufacturing agreements for the product will remain in place throughout Europe. All sales representatives formerly employed by ABR Development will now become employees of Stiefel Laboratories.
Over the next 18 months, Stiefel plans to launch Atlean(R) dermal filler in multiple areas, including parts of Europe, Asia Pacific, Latin America and the Caribbean. The company will continue clinical development of Atlean(R) dermal filler in order to expeditiously submit the product for approval from the Food and Drug Administration (FDA) and other regulatory bodies around the world. Stiefel also expects to develop other products from the ABR portfolio.
According to Bill Humphries, president, Stiefel Laboratories, the company is optimistic that Atlean(R) dermal filler will be approved globally in key aesthetic markets.
"The use of dermal fillers is growing worldwide at a very rapid pace," said Humphries. "Stiefel chose to add Atlean(R) dermal filler to our product portfolio so that we can submit a unique and broader offering of options to our valued physician partners and they can, in turn, offer these products to their patients."
Atlean(R) dermal filler uses a combination of tricalcium phosphate particles (Beta-TCP) suspended in a hyaluronic acid gel. The injectable product is recommended for sculpting and remodelling the face.
Hyaluronic acid occurs naturally in skin tissue, transporting and delivering water to the skin, and contributing to its elasticity. As key ingredients in Atlean(R) dermal filler, hyaluronic acid facilitates an immediate and temporary volumizing effect, and the micro particles of Beta-TCP, by stimulating endogenous synthesis of collagen, contribute to the sustained effects of the product.
The acquisition of ABR gives Stiefel the opportunity to enter the rapidly growing dermal filler market, which is estimated to reach more than $1 billion in 2010 as more people around the world seek rejuvenation options rather than invasive surgery.
About Atlean(R) Dermal Filler
Atlean(R) dermal filler is a bio-resorbable sculpting and modelling dermal volumizer/filler with hyaluronic acid (HA) plus tricalcium phosphate (Beta-TCP) particles. Atlean(R) dermal filler is implanted subcutaneously or intra-dermally.
The gel contains micro-particles of TCP(R), a bio-compatible, biodegradable, immunologically inert, non-toxic, synthetic ceramic belonging to the calcium phosphate chemical family. It is capable of complete and controlled resorption.
Atlean(R) dermal filler has a CE-Mark granted in 2006 and it is commercialized in France and Italy.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%) available in the Duac(R) Care System (CS); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, 0.05% and Olux-E(TM) (clobetasol propionate) Foam, 0.05% also available in the Olux(R) / Olux-E(TM) COMPLETE PACK; Soriatane(R) (acitretin) Capsules available in the Soriatane(R) CK CONVENIENCE KIT; Verdeso(R) (desonide) Foam, 0.05%; Brevoxyl(R)-4 Creamy Wash (benzoyl peroxide 4%) and Brevoxyl(R)-8 Creamy Wash (benzoyl peroxide 8%) packaged in the Brevoxyl(R) Acne Wash Kit; Extina(R) (ketoconazole) Foam, 2%; Oilatum(R) Cleansing Bar; Physiogel(R) Cream; Stieprox(R) (ciclopirox olamine) Shampoo; REVALESKIN(TM) Skin Care Products; and Sarna(R) Lotion. Its wholly- owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.
Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit www.stiefel.com.
CONTACT: Media: Erin Bacher,
Associate Director,
+1-678-889-4039,
erin.bacher@stiefel.com,
Amy Button,
Coordinator,
+1-678-714-4153,
amy.button@stiefel.com,
both of Global Public Relations for Stiefel Laboratories, Inc.
Web site: http://www.stiefel.com
SOURCE: Stiefel Laboratories, Inc.
Press Release
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
